121
Herpes simplex virus infections Yeung-Yue et al.
31 Corey L, Handsfield HH. Genital herpes and public health: addressing a
54 Braig S, Luton D, Sibony O, et al. Acyclovir prophylaxis in late pregnancy
.
global problem. JAMA 2000; 283:791±794.
prevents recurrent genital herpes and viral shedding. Eur J Obstet Gynecol
Reprod Biol 2001; 96:55±58.
Prophylaxis with acyclovir late in pregnancy decreases viral shedding and the risk
of neonatal herpes.
32 Wasserheit JN. Epidemiological synergy. Interrelationships between human
immunodeficiency virus infection and other sexually transmitted diseases. Sex
Transm Dis 1992; 19:61±77.
55 Kimberlin DW, Lin CY, Jacobs RF, et al. Safety and efficacy of high-dose
33 Holmberg SD, Stewart JA, Gerber AR, et al. Prior herpes simplex virus type 2
.
intravenous acyclovir in the management of neonatal herpes simplex virus
infection as a risk factor for HIV infection. JAMA 1988;259:1048±1050.
infections. Pediatrics 2001; 108:230±238.
High dose acyclovir appears to improve morbidity and mortality in newborns with
neonatal herpes.
34 Stamm WE, Handsfield HH, Rompalo AM, et al. The association between
genital ulcer disease and acquisition of HIV infection in homosexual men.
JAMA 1988; 260:1429±1433.
56 Leflore S, Anderson PL, Fletcher CV. A risk-benefit evaluation of aciclovir for
the treatment and prophylaxis of herpes simplex virus infections. Drug Saf
2000; 23:131±142.
35 Hook 3rd EW, Cannon RO, Nahmias AJ, et al. Herpes simplex virus infection
as a risk factor for human immunodeficiency virus infection in heterosexuals. J
Infect Dis 1992; 165:251±255.
57 Ormrod D, Scott LJ, Perry CM. Valaciclovir: a review of its long term utility in
the management of genital herpes simplex virus and cytomegalovirus
infections. Drugs 2000; 59:839±863.
36 Heng MC, Heng SY, Allen SG. Co-infection and synergy of human
immunodeficiency virus-1 and herpes simplex virus-1. Lancet 1994;
343:255±258.
58 Chosidow O, Drouault Y, Leconte-Veyriac F, et al. Famciclovir vs. aciclovir in
.
37 Koelle DM, Abbo H, Peck A, et al. Direct recovery of herpes simplex virus
(HSV)-specific T lymphocyte clones from recurrent genital HSV-2 lesions. J
Infect Dis 1994; 169:956±961.
immunocompetent patients with recurrent genital herpes infections: a parallel-
groups, randomized, double-blind clinical trial. Br J Dermatol 2001; 144:818±
824.
Famciclovir is as effective as acyclovir for the treatment of HSV in immunocom-
petent patients.
38 Schacker T, Ryncarz AJ, Goddard J, et al. Frequent recovery of HIV-1 from
genital herpes simplex virus lesions in HIV±1-infected men. JAMA 1998;
280:61±66.
59 Brigden D, Rosling AE, Woods NC. Renal function after acyclovir intravenous
injection. Am J Med 1982; 73:182±185.
39 Mole L, Ripich S, Margolis D, Holodniy M. The impact of active herpes
simplex virus infection on human immunodeficiency virus load. J Infect Dis
1997; 176:766±770.
60 Spruance SL, Tyring SK, Smith MH, Meng TC. Application of a topical immune
. .
response modifier, resiquimod gel, to modify the recurrence rate of recurrent
genital herpes: a pilot study. J Infect Dis 2001; 184:196±200.
This phase III trial shows that resiquimod, a topical immune response modifier, has
great potential for the treatment of genital herpes.
40 Fleming DT, Wasserheit JN. From epidemiological synergy to public health
policy and practice: the contribution of other sexually transmitted diseases to
sexual transmission of HIV infection. Sex Transm Infect 1999; 75:3±17.
61 Stephenson J. New therapy promising for genital herpes. JAMA 2001;
285:2182±2183.
This is a review of the phase III trial with resiquimod.
41 Moriuchi M, Moriuchi H, Williams R, Straus SE. Herpes simplex virus infection
.
.
induces replication of human immunodeficiency virus type 1. Virology 2000;
278:534±540.
HSV may be able to induce HIV-1 replication through the expression of cytokines.
62 Snoeck R. Antiviral therapy of herpes simplex. Int J Antimicrob Agents 2000;
.
16:157±159.
42 Augenbraun M, Corey L, Reichelderfer P, et al. Herpes simplex virus shedding
This presents a review of the antiviral medications used to treat HSV.
.
and plasma human immunodeficiency virus RNA levels in coinfected women.
Clin Infect Dis 2001; 33:885±890.
No correlation was found between HSV shedding and plasma HIV RNA loads in
this study.
63 Meyers JD, Wade JC, Mitchell CD, et al. Multicenter collaborative trial of
intravenous acyclovir for treatment of mucocutaneous herpes simplex virus
infection in the immunocompromised host. Am J Med 1982; 73:229±235.
43 Fyfe JA, Keller PM, Furman PA, et al. Thymidine kinase from herpes simplex
virus phosphorylates the new antiviral compound, 9-(2-hydroxyethoxymethyl)-
guanine. J Biol Chem 1978; 253:8721±8727.
64 Lazarus HM, Belanger R, Candoni A, et al. Intravenous penciclovir for
treatment of herpes simplex infections in immunocompromised patients:
results of a multicenter, acyclovir-controlled trial. The Penciclovir Immuno-
compromised Study Group. Antimicrob Agents Chemother 1999; 43:1192±
1197.
44 Furman PA, St Clair MH, Spector T. Acyclovir triphosphate is a suicide
inactivator of the herpes simplex virus DNA polymerase. J Biol Chem 1984;
259:9575±9579.
65 Shepp DH, Dandliker PS, Flournoy N, Meyers JD. Sequential intravenous
and twice-daily oral acyclovir for extended prophylaxis of herpes simplex virus
infection in marrow transplant patients. Transplantation 1987; 43:654±658.
45 Barnard DL. Genvir (Flamel Technologies). Curr Opin Investig Drugs 2001;
.
2:622±623.
This article describes a controlled release formulation of acyclovir for twice daily
use.
66 Frechette G, Ramanawski B. Efficacy and safety of famciclovir for the
treatment of HSV infection in HIV+ patients [oral presentation 301].
Presented at the Sixth Annual Canadian Conference of HIV/AIDS Research;
22±25 May 1997; Ottawa, Ontario.
46 Spruance SL. Prophylactic chemotherapy with acyclovir for recurrent herpes
simplex labialis. J Med Virol 1993; (Suppl 1):27±32.
67 Schacker T, Hu HL, Koelle DM, et al. Famciclovir for the suppression of
symptomatic and asymptomatic herpes simplex virus reactivation in HIV-
infected persons. A double-blind, placebo-controlled trial. Ann Intern Med
1998; 128:21±28.
47 Spruance SL, Stewart JC, Rowe NH, et al. Treatment of recurrent herpes
simplex labialis with oral acyclovir. J Infect Dis 1990; 161:185±190.
48 Rooney JF, Straus SE, Mannix ML, et al. Oral acyclovir to suppress
frequently recurrent herpes labialis. A double-blind, placebo-controlled trial.
Ann Intern Med 1993; 118:268±272.
68 Christophers J, Clayton J, Craske J, et al. Survey of resistance of herpes
simplex virus to acyclovir in northwest England. Antimicrob Agents Chemo-
ther 1998; 42:868±872.
49 Spruance SL, Rowe NH, Raborn GW, et al. Peroral famciclovir in the
treatment of experimental ultraviolet radiation-induced herpes simplex labialis:
a double-blind, dose-ranging, placebo-controlled, multicenter trial. J Infect Dis
1999; 179:303±310.
69 Kost RG, Hill EL, Tigges M, Straus SE. Brief report: recurrent acyclovir-
resistant genital herpes in an immunocompetent patient. N Engl J Med 1993;
329:1777±1782.
50 Loveless M, Sacks SL, Harris JR. Famciclovir in the management of first-
70 Field HJ. Herpes simplex virus antiviral drug resistance: current trends and
episode genital herpes. Infect Dis Clin Pract 1997; 6 (Suppl 1):S12±S16.
.
future prospects. J Clin Virol 2001; 21:261±269.
Acyclovir-resistant strains of HSV are rare in the general population, but occur
most frequently in immunocompromized individuals.
51 Kaplowitz LG, Baker D, Gelb L, et al. Prolonged continuous acyclovir
treatment of normal adults with frequently recurring genital herpes simplex
virus infection. The Acyclovir Study Group. JAMA 1991; 265:747±751.
71 Leung DT, Sacks SL. Current recommendations for the treatment of genital
. .
52 Wald A, Zeh J, Barnum G, et al. Suppression of subclinical shedding of
herpes simplex virus type 2 with acyclovir. Ann Intern Med 1996; 124 (1 Pt
1):8±15.
herpes. Drugs 2000; 60:1329±1352.
This is a review of antiviral medications and immunological modalities for the
treatment of HSV.
53 Scott LL, Hollier LM, McIntire D, et al. Acyclovir suppression to prevent clinical
72 Shin YK, Cai GY, Weinberg A, et al. Frequency of acyclovir-resistant herpes
.
.
recurrences at delivery after first episode genital herpes in pregnancy: an open-
simplex virus in clinical specimens and laboratory isolates. J Clin Microbiol
label trial. Infect Dis Obstet Gynecol 2001; 9:75±80.
2001; 39:913±917.
Acyclovir reduced recurrent genital herpes in pregnant women who were
diagnosed with primary genital herpes during the pregnancy.
This study shows that the frequency of acyclovir-resistant strains of HSV are
similar in clinical specimens and laboratory isolates.